MedTrace Logo

TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV

NCT02853526 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2016-08-03

No results posted yet for this study

Summary

To date, there is no treatment strategies for these patients according to American Association of the Study of Liver Disease (AASLD) practice guidelines and Baveno V consensus. Thus, we aim to compare the safety and efficacy of TIPS and conservative treatment (non-selective beta blockers, endoscopic therapy and/or anticoagulation) in patients with PVT and CPTV.

Conditions

  • Portal Vein, Cavernous Transformation of
  • Portal Vein Thrombosis
  • Liver Cirrhosis
  • Bleeding Esophageal Varices

Interventions

PROCEDURE

TIPS

Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (p-TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.

DRUG

Propranolol

Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.

PROCEDURE

Endoscopic therapy

Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.

DRUG

Warfarin

Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.

Sponsors & Collaborators

  • Zaibo Jiang

    lead OTHER

Principal Investigators

  • Zaibo Jiang · Department of Intervention and Vascular Surgery, the Third Affiliated Hospital, Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02853526 on ClinicalTrials.gov